Coya Therapeutics, Inc.
COYA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001835022
No open-market purchases or sales by Coya Therapeutics, Inc. insiders were filed in the last 90 days; 51 institutions reported holding it in 13F filings for Q3 2026, worth $36.6M in total; Greenlight Capital is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:17 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $21.2M (267.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 16, 2026 | Mar 18, 2025 | Mar 19, 2024 | Mar 29, 2023 |
| Revenue | $7.95M | $3.55M | $6.00M | – |
| Operating expenses | $30.5M | $20.8M | $13.9M | $9.81M |
| Research and development | $16.7M | $11.9M | $5.50M | $4.41M |
| Selling, general and administrative | $11.4M | $8.89M | $7.83M | $4.85M |
| Operating income | -$22.6M | -$17.2M | -$7.90M | -$9.81M |
| Income tax | $3.09K | -$720.3K | $723.9K | – |
| Net income | -$21.2M | -$14.9M | -$7.99M | -$12.2M |
| EPS, basic | $-1.27 | $-0.98 | $-0.79 | $-4.73 |
| EPS, diluted | $-1.27 | $-0.98 | $-0.79 | $-4.73 |
| Weighted shares, basic | 16.7M | 15.2M | 10.2M | 2.59M |
| Weighted shares, diluted | 16.7M | 15.2M | 10.2M | 2.59M |
| Margins and growth | ||||
| Operating margin | -283.9% | -485.4% | -131.7% | – |
| Net margin | -267.1% | -418.7% | -133.1% | – |
| Revenue growth, year over year | +123.6% | −40.8% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 16, 2026 | Mar 18, 2025 | Mar 19, 2024 | Mar 29, 2023 |
| Cash and equivalents | $46.8M | $38.3M | $32.6M | $5.93M |
| Total current assets | $49.9M | $44.3M | $41.2M | $7.18M |
| Property, plant and equipment | $11.2K | $38.6K | $65.9K | $93.3K |
| Total assets | $50.0M | $44.3M | $41.3M | $8.40M |
| Accounts payable | $1.06M | $1.59M | $1.16M | $1.82M |
| Total current liabilities | $5.87M | $3.82M | $5.05M | $3.82M |
| Total liabilities | $6.92M | $4.77M | $5.63M | $16.8M |
| Shareholders' equity | $43.0M | $39.6M | $35.6M | -$8.39M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 16, 2026 | Mar 18, 2025 | Mar 19, 2024 | Mar 29, 2023 |
| Operating cash flow | -$10.7M | -$10.3M | -$11.2M | -$7.24M |
| Stock-based compensation | $4.29M | $2.66M | $872.2K | $207.3K |
| Investing cash flow | -$1.16M | -$25.0K | -$543.2K | -$525.0K |
| Financing cash flow | $20.4M | $16.0M | $38.4M | $9.36M |
| Ratio | ||||
| Stock-based compensation, % of revenue | 54.0% | 74.9% | 14.5% | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 5, 2026 | 23.5M | +12.1% | SEC |
| Aug 7, 2026 | 23.5M | +40.3% | SEC |
| May 8, 2026 | 23.5M | +40.3% | SEC |
| Mar 12, 2026 | 23.5M | +40.3% | SEC |
| Nov 10, 2025 | 20.9M | +25.2% | SEC |
| Aug 8, 2025 | 16.7M | +9.9% | SEC |
| May 9, 2025 | 16.7M | +14.4% | SEC |
| Mar 14, 2025 | 16.7M | +15.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.